Related Experiment Videos
Hepatitis delta virus and the host response: current status and future perspectives
H C Thomas1, P Karayiannis, J Monjardino
1Department of Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London University, U.K.
Progress in Clinical and Biological Research
|January 1, 1993
Summary
Recombinant vaccinia virus immunization controlled hepatitis D virus (HDV) viraemia in hepatitis B virus (HBV) carriers. This suggests a potential new vaccine strategy against HDV infection.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) carriers are susceptible to superinfection with hepatitis D virus (HDV).
- Current therapeutic options for HDV infection are limited, necessitating novel treatment strategies.
Purpose of the Study:
- To investigate the potential of recombinant vaccinia virus as a vaccine to control HDV viraemia.
- To explore the role of cell-mediated immunity, specifically cytotoxic T lymphocyte (CTL) responses, in controlling HDV infection.
Main Methods:
- Immunization of subjects with recombinant vaccinia virus expressing HDV antigens.
- Assessment of viraemia levels following HDV superinfection.
- Evaluation of cellular immune responses, including CTLs.
Main Results:
- Recombinant vaccinia virus immunization effectively controlled viraemia after HDV superinfection.
- The protective effect appears to be mediated by CTL responses against HDV.
Conclusions:
- Recombinant vaccinia virus immunization offers a promising strategy for controlling HDV infection in established HBV carriers.
- Interferon's therapeutic effect may involve the induction of HDV-specific CTL responses, warranting further investigation.
- The precise mechanisms of immune protection and interferon's direct effects require additional research.